The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 231-238

  Meuleman, Philip ^a   Leroux Roels, Geert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Animal model; Antiviral therapy; Chimeric mice; Chimpanzee; Hepatitis B; Hepatitis C; Neutralizing antibodies; uPA; Viral hepatitis

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; MYRIOMYCIN; NEUTRALIZING ANTIBODY; PEGINTERFERON; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE PALMITOYLTRANSFERASE; UNCLASSIFIED DRUG; UROKINASE; VIRUS RECEPTOR;

ANTIVIRAL THERAPY; APOPTOSIS; CHIMPANZEE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER METABOLISM; LIVER PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCID MOUSE; TRANSGENE; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MICE; MICE, SCID; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ANIMALIA; HEPATITIS B VIRUS; HEPATITIS C VIRUS; MUS; PAN;

EID: 56349163205     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.07.006     Document Type: Review

References (74)

1. Abe K., Kurata T., Teramoto Y., Shiga J., and Shikata T. Lack of susceptibility of various primates and woodchucks to hepatitis C virus. J. Med. Primatol. 22 (1993) 433-434
2. Aizaki H., Morikawa K., Fukasawa M., Hara H., Inoue Y., Tani H., Saito K., Nishijima M., Hanada K., Matsuura Y., Lai M.M., Miyamura T., Wakita T., and Suzuki T. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J. Virol. 82 (2008) 5715-5724
3. Alter M.J. Epidemiology and prevention of hepatitis B. Semin. Liver Dis. 23 (2003) 39-46
4. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39 (2004) 1469-1475
5. Carroll S.S., Davies M., Handt L., Koeplinger K., Zhang R., Ludmerer S., MacCoss M., Hazuda D., and Olsen D. Robust suppression of viral replication by a nucleoside polymerase inhibitor in chimpanzees infected with hepatitis C virus. Hepatology 44 Suppl. 1 (2006) 535A
6. Chen C.M., He Y., Lu L., Lim H.B., Tripathi R.L., Middleton T., Hernandez L.E., Beno D.W., Long M.A., Kati W.M., Bosse T.D., Larson D.P., Wagner R., Lanford R.E., Kohlbrenner W.E., Kempf D.J., Pilot-Matias T.J., and Molla A. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob. Agents Chemother. 51 (2007) 4290-4296
7. Dandri M., Burda M.R., Gocht A., Torok E., Pollok J.M., Rogler C.E., Will H., and Petersen J. Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. Hepatology 34 (2001) 824-833
8. Dandri M., Burda M.R., Zuckerman D.M., Wursthorn K., Matschl U., Pollok J.M., Rogiers X., Gocht A., Kock J., Blum H.E., von Weizsacker F., and Petersen J. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J. Hepatol. 42 (2005) 54-60
9. Dubuisson J., Helle F., and Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol. 10 (2008) 821-827
10. Feinstone S.M., Alter H.J., Dienes H.P., Shimizu Y., Popper H., Blackmore D., Sly D., London W.T., and Purcell R.H. Non-A, non-B hepatitis in chimpanzees and marmosets. J. Infect. Dis. 144 (1981) 588-598
11. Ferir G., Kaptein S., Neyts J., and De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev. Med. Virol. 18 (2008) 19-34
12. Flisiak R., Horban A., Gallay P., Bobardt M., Selvarajah S., Wiercinska-Drapalo A., Siwak E., Cielniak I., Higersberger J., Kierkus J., Aeschlimann C., Grosgurin P., Nicolas-Metral V., Dumont J.M., Porchet H., Crabbe R., and Scalfaro P. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47 (2008) 817-826
13. Garson J.A., Whitby K., Watkins P., and Morgan A.J. Lack of susceptibility of the cottontop tamarin to hepatitis C infection. J. Med. Virol. 52 (1997) 286-288
14. Guidotti L.G., Matzke B., Schaller H., and Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69 (1995) 6158-6169
15. Gupta S., Rajvanshi P., Sokhi R., Slehria S., Yam A., Kerr A., and Novikoff P.M. Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology 29 (1999) 509-519
16. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer Jr. H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., and Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140 (2004) 346-355
17. Heathcote E.J. Antiviral therapy: chronic hepatitis C. J. Viral Hepat. 14 Suppl. 1 (2007) 82-88
18. Heckel J.L., Sandgren E.P., Degen J.L., Palmiter R.D., and Brinster R.L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62 (1990) 447-456
19. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., Forns X., Erhardt A., Cronlein J., Chaves R.L., Yong C.L., Nehmiz G., and Steinmann G.G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
20. Hsu E.C., Hsi B., Hirota-Tsuchihara M., Ruland J., Iorio C., Sarangi F., Diao J., Migliaccio G., Tyrrell D.L., Kneteman N., and Richardson C.D. Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat. Biotechnol. 21 (2003) 519-525
21. Ilan E., Burakova T., Dagan S., Nussbaum O., Lubin I., Eren R., Ben-Moshe O., Arazi J., Berr S., Neville L., Yuen L., Mansour T.S., Gillard J., Eid A., Jurim O., Shouval D., Reisner Y., and Galun E. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 29 (1999) 553-562
22. Ilan E., Arazi J., Nussbaum O., Zauberman A., Eren R., Lubin I., Neville L., Ben-Moshe O., Kischitzky A., Litchi A., Margalit I., Gopher J., Mounir S., Cai W., Daudi N., Eid A., Jurim O., Czerniak A., Galun E., and Dagan S. The hepatitis C virus (HCV)-trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 185 (2002) 153-161
23. Inoue K., Sekiyama K., Yamada M., Watanabe T., Yasuda H., and Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 38 (2003) 567-572
24. Inoue K., Umehara T., Ruegg U.T., Yasui F., Watanabe T., Yasuda H., Dumont J.M., Scalfaro P., Yoshiba M., and Kohara M. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45 (2007) 921-928
25. Julander J.G., Sidwell R.W., and Morrey J.D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 55 (2002) 27-40
26. Julander J.G., Colonno R.J., Sidwell R.W., and Morrey J.D. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res. 59 (2003) 155-161
27. Kapadia S.B., and Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2561-2566
28. Kaplan D.E., Sugimoto K., Newton K., Valiga M.E., Ikeda F., Aytaman A., Nunes F.A., Lucey M.R., Vance B.A., Vonderheide R.H., Reddy K.R., McKeating J.A., and Chang K.M. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132 (2007) 654-666
29. Kaul A., Woerz I., Meuleman P., Leroux-Roels G., and Bartenschlager R. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J. Virol. 81 (2007) 13168-13179
30. Kneteman N.M., Weiner A.J., O'Connell J., Collett M., Gao T., Aukerman L., Kovelsky R., Ni Z.J., Zhu Q., Hashash A., Kline J., Hsi B., Schiller D., Douglas D., Tyrrell D.L., and Mercer D.F. Anti-HCV therapies in chimeric SCID-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43 (2006) 1346-1353
31. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., and Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
32. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., Sakellariou G., Intrator L., Bartosch B., Pawlotsky J.M., and Cosset F.L. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79 (2005) 6023-6034
33. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., Ball J.K., McKeating J.A., Kneteman N.M., and Burton D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14 (2008) 25-27
34. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
35. Lindenbach B.D., Meuleman P., Ploss A., Vanwolleghem T., Syder A.J., McKeating J.A., Lanford R.E., Feinstone S.M., Major M.E., Leroux-Roels G., and Rice C.M. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3805-3809
36. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M., and McKeating J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10149-10154
37. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
38. +/+SCID mice with a humanised liver. Proceedings of the 26th Cologne Workshop on Dope Analysis. Cologne, Germany (2008)
39. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., and Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7 (2001) 927-933
40. Meuleman P., Vanlandschoot P., and Leroux-Roels G. A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice. Biochem. Biophys. Res. Commun. 308 (2003) 375-378
41. Meuleman P., Libbrecht L., De Vos R., de Hemptinne B., Gevaert K., Vandekerckhove J., Roskams T., and Leroux-Roels G. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41 (2005) 847-856
42. Meuleman P., Steyaert S., Libbrecht L., Couvent S., Van Houtte F., Clinckspoor F., de Hemptinne B., Roskams T., Vanlandschoot P., and Leroux-Roels G. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. Clin. Chim. Acta 366 (2006) 156-162
43. Meuleman P., Libbrecht L., Wieland S., De Vos R., Habib N., Kramvis A., Roskams T., and Leroux-Roels G. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J. Virol. 80 (2006) 2797-2807
44. Meuleman, P., Hesselgesser, J., Paulson, M., Vanwolleghem, T., Desombere, I., Reiser, H., Leroux-Roels, G., 2008. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology, in press.
45. Muchmore E.A. Chimpanzee models for human disease and immunobiology. Immunol. Rev. 183 (2001) 86-93
46. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
47. Paeshuyse J., Kaul A., De Clercq E., Rosenwirth B., Dumont J.M., Scalfaro P., Bartenschlager R., and Neyts J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43 (2006) 761-770
48. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., Patel A.H., Meisel H., Baumert J., Viazov S., Rispeter K., Blum H.E., Roggendorf M., and Baumert T.F. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 6025-6030
49. Petersen J., Dandri M., Gupta S., and Rogler C.E. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 310-315
50. Petersen J., Dandri M., Mier W., Lutgehetmann M., Volz T., von Weizsacker F., Haberkorn U., Fischer L., Pollok J.M., Erbes B., Seitz S., and Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26 (2008) 335-341
51. Prince A.M., and Brotman B. Perspectives on hepatitis B studies with chimpanzees. ILAR J. 42 (2001) 85-88
52. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Yong C.L., Nehmiz G., and Steinmann G.G. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
53. Rhim J.A., Sandgren E.P., Degen J.L., Palmiter R.D., and Brinster R.L. Replacement of diseased mouse liver by hepatic cell transplantation. Science 263 (1994) 1149-1152
54. Rhim J.A., Sandgren E.P., Palmiter R.D., and Brinster R.L. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4942-4946
55. Sandgren E.P., Palmiter R.D., Heckel J.L., Daugherty C.C., Brinster R.L., and Degen J.L. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66 (1991) 245-256
56. Scheel T.K., Gottwein J.M., Jensen T.B., Prentoe J.C., Hoegh A.M., Alter H.J., Eugen-Olsen J., and Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 997-1002
57. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
58. Sithebe N.P., Kew M.C., Mphahlele M.J., Paterson A.C., Lecatsas G., Kramvis A., and de Klerk W. Lack of susceptibility of Chacma baboons (Papio ursinus orientalis) to hepatitis C virus infection. J. Med. Virol. 66 (2002) 468-471
59. Tateno C., Yoshizane Y., Saito N., Kataoka M., Utoh R., Yamasaki C., Tachibana A., Soeno Y., Asahina K., Hino H., Asahara T., Yokoi T., Furukawa T., and Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165 (2004) 901-912
60. Tsuge M., Hiraga N., Takaishi H., Noguchi C., Oga H., Imamura M., Takahashi S., Iwao E., Fujimoto Y., Ochi H., Chayama K., Tateno C., and Yoshizato K. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42 (2005) 1046-1054
61. Umehara T., Sudoh M., Yasui F., Matsuda C., Hayashi Y., Chayama K., and Kohara M. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem. Biophys. Res. Commun. 346 (2006) 67-73
62. Uprichard S.L., Boyd B., Althage A., and Chisari F.V. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 773-778
63. Vanwolleghem T., Meuleman P., Libbrecht L., Roskams T., De Vos R., and Leroux-Roels G. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133 (2007) 1144-1155
64. Vanwolleghem T., Bukh J., Meuleman P., Desombere I., Meunier J.C., Alter H., Purcell R.H., and Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47 (2008) 1846-1855
65. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11 (2005) 791-796
66. Walter E., Keist R., Niederost B., Pult I., and Blum H.E. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24 (1996) 1-5
67. Watashi K., Ishii N., Hijikata M., Inoue D., Murata T., Miyanari Y., and Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19 (2005) 111-122
68. Weber O., Schlemmer K.H., Hartmann E., Hagelschuer I., Paessens A., Graef E., Deres K., Goldmann S., Niewoehner U., Stoltefuss J., Haebich D., Ruebsamen-Waigmann H., and Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 54 (2002) 69-78
69. Xie Z.C., Riezu-Boj J.I., Lasarte J.J., Guillen J., Su J.H., Civeira M.P., and Prieto J. Transmission of hepatitis C virus infection to tree shrews. Virology 244 (1998) 513-520
70. Yan R.Q., Su J.J., Huang D.R., Gan Y.C., Yang C., and Huang G.H. Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J. Cancer Res. Clin. Oncol. 122 (1996) 283-288
71. Yanagi M., Purcell R.H., Emerson S.U., and Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 8738-8743
72. Yu M.Y., Bartosch B., Zhang P., Guo Z.P., Renzi P.M., Shen L.M., Granier C., Feinstone S.M., Cosset F.L., and Purcell R.H. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7705-7710
73. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., and Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9294-9299
74. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin. Liver Dis. 26 (2006) 171-180